DBV Technologies S.A. (EPA:DBV)
3.765
+0.045 (1.21%)
Mar 6, 2026, 5:35 PM CET
DBV Technologies Employees
DBV Technologies had 110 employees as of December 31, 2024. The number of employees increased by 5 or 4.76% compared to the previous year.
Employees
110
Change (1Y)
5
Growth (1Y)
4.76%
Revenue / Employee
€40,080
Profits / Employee
€911,546
Market Cap
1.04B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Inventiva | 84 |
| Nanobiotix | 103 |
| Valneva SE | 700 |
| MedinCell | 145 |
| Genfit | 188 |
| Transgene | 147 |
| Cellectis | 222 |
| ABIVAX Société Anonyme | 67 |
DBV Technologies News
- 1 day ago - DBV Technologies S.A. (DBVT) Presents at American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting - Slideshow - Seeking Alpha
- 1 day ago - DBV Technologies to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 4 days ago - DBV Technologies Peanut Patch Meets Primary Endpoint In Phase 3 VITESSE Study - Nasdaq
- 5 days ago - DBVT Shares Promising Phase 3 Trial Results for Viaskin Peanut - GuruFocus
- 5 days ago - DBV Technologies S.A.: DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - Finanz Nachrichten
- 5 days ago - DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting - GlobeNewsWire
- 23 days ago - DBV Technologies To Present Additional VITESSE Phase 3 Data In Peanut-Allergic Children - Nasdaq
- 23 days ago - DBV Technologies S.A.: DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - Finanz Nachrichten